A new investigation suggests compounded GLP-1 products remain widely used even as shortages for semaglutide and tirzepatide ease. Researchers, writing in JAMA Health Forum, examined compounding patterns following supply disruptions and reported that facilities continued producing GLP-1 receptor agonists using compounded formulations that include added ingredients. The findings add nuance to the ‘shortage relief’ narrative and raise continued monitoring questions for clinicians and payers as compounded products compete with branded supply.